|1.||Leray, E: 3 articles (12/2011 - 02/2006)|
|2.||Le Page, E: 3 articles (12/2011 - 02/2006)|
|3.||Edan, G: 3 articles (12/2011 - 02/2006)|
|4.||Deburghgraeve, Véronique: 1 article (01/2015)|
|5.||Cardiet, Isabelle: 1 article (01/2015)|
|6.||Lester, Marie-Antoinette: 1 article (01/2015)|
|7.||Le Page, Emmanuelle: 1 article (01/2015)|
|8.||Edan, Gilles: 1 article (01/2015)|
|9.||Leray, Emmanuelle: 1 article (01/2015)|
|10.||Filippi, M: 1 article (12/2011)|
|1.||Relapsing-Remitting Multiple Sclerosis
06/01/2005 - "Mitoxantrone (mitox) has been shown to be effective for secondary progressive (SP) and relapsing-remitting multiple sclerosis (MS). "
12/01/2011 - "The long-term impact of interferon-beta-1b (IFN) might be improved by short-term immunosuppression with mitoxantrone (MITOX) in aggressive relapsing-remitting multiple sclerosis (ARMS) patients. "
09/01/2007 - "We investigated the clinical and MRI effects of mitoxantrone (MITOX) administered to 45 patients during the first five years of highly active relapsing-remitting multiple sclerosis. "
02/01/2006 - "On the basis of the French and British (FB) MS Trial, Mitoxantrone (MITOX) was approved by the AFSAPPS in October 2003 in patients with aggressive multiple sclerosis (MS), given as induction therapy monthly for 6 months (ELSEP). "
07/01/2011 - "To determine long-term safety profile of mitoxantrone (MITOX) in multiple sclerosis (MS). "
08/01/2004 - "As a rare complication of mitoxantrone (MITOX) therapy in multiple sclerosis (MS), a therapy-related acute leukaemia (TRAL) may develop. "
01/01/2015 - "Our study aimed to describe safety and neurological impact of alemtuzumab as last-line rescue therapy in aggressive multiple sclerosis (MS) patients, previously treated by Mitoxantrone (MITOX). "
|3.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
06/01/1986 - "In a multi-institutional study 26 patients with refractory acute myeloid leukemia were entered into a phase I/II study of HD-ara-C and mitox. "
02/01/1989 - "Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia."
01/01/1993 - "193 patients with relapsed or refractory acute myeloid leukemia (AML) were entered into a prospective randomized comparison of high-dose versus intermediate dose cytosine arabinoside (AraC) both combined with mitoxantrone (mitox) according to the previously established sequential HD-AraC/mitox regimen (S-HAM). "
|4.||Lymphoproliferative Disorders (Lymphoproliferative Disorder)
|5.||Hodgkin Disease (Hodgkin's Disease)
|5.||Messenger RNA (mRNA)
|7.||Etoposide (VP 16)
|1.||Combination Drug Therapy (Combination Chemotherapy)
|2.||Transplantation (Transplant Recipients)